Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health

Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates

Africa’s Biggest Drugmaker Can Help Ease Obesity Medicine Supply Crunch

11 Best Low Price Pharma Stocks To Invest In

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

Bill Miller’s Latest 13 Stock Picks

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024

Do cash-gushing stocks outperform the S&P 500? Here’s what history has to say.

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada

UK's Theramex sees no impact to HRT products supply after CMA probe

Competition watchdog says HRT drug deal could raise prices

UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns

UK watchdog says Theramex-Viatris deal raises competition concerns

UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent